Phio Pharmaceuticals Corp SEC Filings

Welcome to our dedicated page for Phio Pharmaceuticals SEC filings (Ticker: PHIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The Phio Pharmaceuticals Corp. (NASDAQ: PHIO) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Phio is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology in immuno-oncology, with a lead program, PH-762, targeting the PD-1 gene in skin cancers.

Through this page, you can review current and historical Forms 8-K in which Phio reports material events. Recent 8-K filings describe clinical milestones for the Phase 1b trial of PH-762 (NCT 06014086), such as completion of enrollment, interim pathology results, and Safety Monitoring Committee findings that no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed at reported dose levels. Other 8-Ks detail warrant inducement agreements, gross proceeds from warrant exercises, and the terms of new warrants and placement agent warrants.

Phio’s proxy materials, including its Definitive Proxy Statement on Schedule DEF 14A, outline governance and compensation matters. These filings cover the election of directors, ratification of the independent registered public accounting firm, amendments to the 2020 Long Term Incentive Plan to increase share availability, and advisory votes on executive compensation and the frequency of such votes. They also describe the conduct of the annual meeting and voting results on each proposal.

As Phio advances its INTASYL platform and PH-762 program, investors can use this filings page to monitor financial reporting, capital structure changes, and corporate actions. Stock Titan enhances these documents with AI-powered summaries that highlight key points in complex filings, helping readers quickly identify items such as clinical development updates, financing terms, and board decisions without manually parsing every section.

In addition, the filings page links to disclosures about nonclinical protocol acceptance by the FDA, agreements for cGMP manufacturing of PH-762, and other events that influence the company’s development and financing strategy. For those analyzing PHIO, this centralized view of 8-Ks, proxy statements, and related filings offers a concise way to follow the regulatory record that underpins Phio’s public communications.